Advaxis, Inc. (NASDAQ:ADXS)’s share price was down 7.7% during mid-day trading on Monday after the company announced weaker than expected quarterly earnings. The company traded as low as $6.82 and last traded at $6.84. Approximately 570,320 shares were traded during mid-day trading, an increase of 2% from the average daily volume of 556,414 shares. The stock had previously closed at $7.41.

The biotechnology company reported ($0.80) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.27). Advaxis had a negative return on equity of 86.53% and a negative net margin of 655.66%. The business had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $3.43 million.

Several equities research analysts have recently commented on the stock. Cantor Fitzgerald set a $19.00 price target on shares of Advaxis and gave the company a “buy” rating in a research report on Thursday, July 6th. BidaskClub upgraded Advaxis from a “sell” rating to a “hold” rating in a research note on Friday, August 25th. ValuEngine upgraded Advaxis from a “strong sell” rating to a “sell” rating in a research note on Friday, September 8th. Finally, HC Wainwright set a $23.00 price objective on Advaxis and gave the company a “buy” rating in a research note on Wednesday, June 14th.

Hedge funds have recently bought and sold shares of the business. Stevens Capital Management LP purchased a new stake in shares of Advaxis during the 1st quarter worth approximately $105,000. Voya Investment Management LLC raised its holdings in shares of Advaxis by 20.3% during the 2nd quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 2,975 shares in the last quarter. Cutler Capital Management LLC purchased a new stake in shares of Advaxis during the 2nd quarter worth approximately $130,000. Northern Capital Management LLC raised its holdings in shares of Advaxis by 14.6% during the 2nd quarter. Northern Capital Management LLC now owns 20,775 shares of the biotechnology company’s stock worth $135,000 after acquiring an additional 2,650 shares in the last quarter. Finally, Stonebridge Capital Management Inc. purchased a new stake in shares of Advaxis during the 2nd quarter worth approximately $146,000. Institutional investors and hedge funds own 48.78% of the company’s stock.

The firm has a 50 day moving average price of $6.50 and a 200-day moving average price of $7.51. The firm’s market cap is $207.57 million.

ILLEGAL ACTIVITY NOTICE: “Advaxis, Inc. (ADXS) Shares Down 7.7% After Earnings Miss” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.watchlistnews.com/advaxis-inc-adxs-shares-down-7-7-after-earnings-miss-2/1559356.html.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.